Biotec Pharmacon ASA

Profile
More about Biotec Pharmacon
  • News

    Biotec Pharmacon reports on neuroblastoma study

    Biotec Pharmacon ASA is announcing the final results from an early phase (I/II) study on combining Soluble Beta-Glucan (SBG) with anti-cancer antibodies in treatment of neuroblastoma in children. The study, performed at Memorial Sloan-Kettering Cancer Center, showed that the combined treatm ... more

    Biotec Pharmacon receives promising interim results from animal study

    Biotec Pharmacon ASA has received an interim data report from the second animal study in diabetic mice. The results confirm the finding from the first study showing that a 2% aqueous solution of SBG has good wound healing capability. An important goal with the second study was to investigat ... more

    Svein Lien appointed new CEO of Biotec Pharmacon ASA

    Svein Lien has been appointed new CEO of Biotec Pharmacon, following Lars Viksmoen's decision to resign after 3 years as CEO. Svein Lien will assume the position with effect from 15 March, 2010. Svein Lien (55) joins the company with a financial background and extensive experience from tec ... more